Poolbeg Pharma PLC (AIM:POLB)
London · Delayed Price · Currency is GBP · Price in GBX 6.20
-0.20 (-3.06%)
Oct 15, 2026, 2:11 PM GMT
Poolbeg Pharma Balance Sheet
Financials in millions GBP. Fiscal year is January - December.
Millions GBP. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 4.82 | 7.71 | 7.82 | 12.17 | 16.19 | 20.95 |
Cash & Short-Term Investments | 4.82 | 7.71 | 7.82 | 12.17 | 16.19 | 20.95 |
Cash Growth | -51.62% | -1.42% | -35.72% | -24.84% | -22.70% | - |
Accounts Receivable | 0.04 | 0.07 | 0.02 | - | - | 0.01 |
Other Receivables | 0.4 | 0.22 | 0.25 | 0.66 | 0.08 | 0.05 |
Receivables | 0.44 | 0.29 | 0.27 | 0.66 | 0.08 | 0.06 |
Prepaid Expenses | 0.2 | 0.27 | 0.47 | 0.67 | 0.88 | 0.45 |
Total Current Assets | 5.46 | 8.27 | 8.56 | 13.5 | 17.16 | 21.46 |
Other Intangible Assets | 1.69 | 1.67 | 1.68 | 1.93 | 2.13 | 1.56 |
Total Assets | 7.15 | 9.94 | 10.25 | 15.43 | 19.29 | 23.02 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 0.44 | 0.15 | 0.17 | 0.08 | 0.29 | 0.08 |
Accrued Expenses | - | 1.18 | 0.79 | 0.9 | 0.67 | 0.36 |
Other Current Liabilities | - | 0.01 | 0.02 | 0.01 | 0 | 0 |
Total Current Liabilities | 0.44 | 1.34 | 0.97 | 0.99 | 0.97 | 0.44 |
Total Liabilities | 0.44 | 1.34 | 0.97 | 0.99 | 0.97 | 0.44 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.14 | 0.14 | 0.1 | 0.1 | 0.1 | 0.1 |
Additional Paid-In Capital | 27.54 | 27.54 | 23.1 | 23.1 | 23.1 | 23.1 |
Retained Earnings | -24.38 | -22.44 | -16.74 | -10.95 | -7.02 | -2.34 |
Comprehensive Income & Other | 3.41 | 3.36 | 2.82 | 2.2 | 2.15 | 1.72 |
Shareholders' Equity | 6.71 | 8.6 | 9.27 | 14.44 | 18.32 | 22.58 |
Total Liabilities & Equity | 7.15 | 9.94 | 10.25 | 15.43 | 19.29 | 23.02 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Cash (Debt) | 4.82 | 7.71 | 7.82 | 12.17 | 16.19 | 20.95 |
Net Cash Growth | -51.62% | -1.42% | -35.72% | -24.84% | -22.70% | - |
Net Cash Per Share | 0.01 | 0.01 | 0.02 | 0.02 | 0.03 | 0.07 |
Filing Date Shares Outstanding | 705.1 | 705.1 | 500 | 500 | 500 | 500 |
Total Common Shares Outstanding | 705.1 | 697.2 | 500 | 500 | 500 | 500 |
Working Capital | 5.02 | 6.93 | 7.59 | 12.51 | 16.19 | 21.02 |
Book Value Per Share | 0.01 | 0.01 | 0.02 | 0.03 | 0.04 | 0.05 |
Tangible Book Value | 5.02 | 6.93 | 7.59 | 12.51 | 16.19 | 21.02 |
Tangible Book Value Per Share | 0.01 | 0.01 | 0.02 | 0.03 | 0.03 | 0.04 |